Eliminating the Hidden Recovery Gap in Elite Sport
BioSensr was born out of a shared frustration: watching elite athletic careers repeatedly stalled or derailed by devastating, recurring muscle injuries. While modern sports analytics excel at measuring external workloads like GPS distance or static mechanical force, they remain blind to underlying neural exhaustion.
We established BioSensr to close this critical return-to-play blind spot. By transforming laboratory-grade surface electromyography (sEMG) into motion-resistant, flexible field wearables, we deliver objective neuromuscular clarity directly to the sideline. Our mission is to empower medical departments and high-performance managers with the definitive physiological insights required to safeguard athlete longevity and performance.
Leadership & Strategy
Jan-Willem van der Wallen (left) and Dr. Jett van der Wallen (right)
Jan-Willem (John) van der Wallen
Director & Commercial Lead
Background: Cornell University Alumnus | 35+ Years Senior Executive Experience
Expertise: Corporate Governance, Institutional Capital Growth, and Deal Structuring
John brings extensive corporate leadership and operational architecture to BioSensr. Having previously managed institutional assets and strategic funds at Bankers Trust, serving as the Fund Manager for the Colonial First State Hotel Fund, he provides the robust commercial framework required to transition deep-tech innovations into global enterprise markets.
John specialises in joint-venture deal structuring and corporate execution, ensuring BioSensr’s commercial pilot partnerships, international patent frameworks, and medical quality management systems (ISO 13485) are scaled to strict enterprise-grade standards.
Dr. Jett van der Wallen
Managing Director & Technical Lead
Background: PhD in Biomedical Engineering (USYD) | Elite Athletic Focus
Ecosystem: Alumnus of Nucleate, Incubate Accelerator, and Sydney Knowledge Hub
As both a competitive athlete and a biomedical engineer, Jett spent years observing a systemic pattern: players enduring rehabilitation periods and passing traditional strength clearance tests, only to suffer re-injuries within weeks of returning to the field.
Recognising this as a critical engineering deficit, where muscle force looks recovered but underlying neuromuscular pathways remain fatigued, he engineered the BioSensr platform to map true active physiology. Jett specialises in field-deployable biosignal architectures, embedded systems processing, and hardware-software pipeline integration.
Strategic Roadmap
Short Term (0–12 Mos)
- Complete Australian EMC hardware compliance and advance the ISO 13485 medical device framework pathway.
- Progress active PCT patent filings and finalise the University of Sydney longitudinal validation study.
- Expand elite field dataset scale through on-field professional pilot deployments.
Medium Term (2–5 Yrs)
- Scale software platform distribution across premium Australian sporting codes (including NRL, Rugby Union, AFL, Soccer).
- Expand local manufacturing scale and wireless infrastructure deployments.
- Grow high-margin software data operations and execute market entry across North American and European elite athletic networks.
Long Term (5–10 Yrs)
- Establish BioSensr™ as the baseline standard for direct neuromuscular data analytics across global elite sport.
- Expand software platform footprint into broader human health, defense, and adjacent rehabilitation applications.
- Pursue targeted strategic enterprise corporate acquisition or public IPO exit pathways.